Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: A single centre experience from the GMMG-HD6 and -HD7 trials
Số trang: 11
Loại file: pdf
Dung lượng: 1.58 MB
Lượt xem: 7
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
While quadruplet induction therapies deepen responses in newly diagnosed multiple myeloma patients, their impact on peripheral blood stem cell (PBSC) collection remains incompletely understood. This analysis aims to evaluate the effects of prolonged lenalidomide induction and isatuximab- or elotuzumab-containing quadru‑ plet induction therapies on PBSC mobilization and collection.
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Multiple myeloma Stem cell mobilization Induction therapy Peripheral blood stem cell Peripheral bloodGợi ý tài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 171 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 142 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 119 0 0 -
12 trang 93 0 0
-
19 trang 74 0 0
-
17 trang 64 0 0
-
9 trang 43 0 0
-
12 trang 38 0 0
-
Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer
17 trang 37 0 0 -
13 trang 37 0 0
-
11 trang 37 0 0
-
Tracking tumor alteration in glioma through serum fibroblast activation protein combined with image
10 trang 35 0 0 -
Evaluating the prognostic value of CD56 in pediatric acute myeloid leukemia
9 trang 35 0 0 -
11 trang 34 0 0
-
9 trang 33 0 0
-
14 trang 32 0 0
-
9 trang 32 0 0
-
8 trang 32 0 0
-
21 trang 32 0 0